Researchers from Helmholtz Munich and Ludwig-Maximilians-Universität have revealed that the SARS-CoV-2 spike protein can persist in the brain and skull bone marrow for up to four years post-infection, potentially leading to chronic inflammation and neurodegenerative conditions associated with Long COVID. Their study utilized a novel AI-powered imaging technique to visualize spike protein distribution in tissue samples from infected patients and mice, finding elevated concentrations in vulnerable areas like the meninges and skull’s bone marrow. The research, led by Prof. Ali Ertürk, indicates that mRNA COVID-19 vaccines, such as BioNTech/Pfizer, significantly decrease spike protein buildup in the brain, though some residual protein remains, posing ongoing risks. The team emphasizes the need for targeted therapies to address the long-term neurological impacts of COVID-19, as millions worldwide may harbor this protein after infection. As diagnosing and treating Long COVID becomes increasingly crucial, the study opens promising avenues for identifying inflammatory markers and developing specialized interventions. Prof. Ertürk highlights that these findings not only enhance scientific understanding but also present significant societal implications, especially amidst the continued global impact of COVID-19. Further research is necessary to evaluate these effects in humans and develop effective treatments.
